Navigation Links
How These Medical Instruments Stocks are Faring? -- Tandem Diabetes Care, C. R. Bard, Glaukos, and OraSure Technologies
Date:2/22/2017

NEW YORK, February 22, 2017 /PRNewswire/ --

On Tuesday, February 21, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Medical Instruments & Supplies equities this morning: Tandem Diabetes Care Inc. (NASDAQ: TNDM), C. R. Bard Inc. (NYSE: BCR), Glaukos Corporation (NYSE: GKOS), and OraSure Technologies Inc. (NASDAQ: OSUR). Download the free research reports on these stocks today:

http://stock-callers.com/registration

Tandem Diabetes Care  

San Diego, California headquartered Tandem Diabetes Care Inc.'s stock finished Tuesday's session 4.08% lower at $2.35 with a total volume of 238,586 shares traded. Tandem Diabetes Care's shares have advanced 4.44% in the past three months. The Company's shares are trading above its 50-day moving average by 0.21%. Shares of Tandem Diabetes Care, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have a Relative Strength Index (RSI) of 48.72. See our free and comprehensive research report on TNDM at:

http://stock-callers.com/registration/?symbol=TNDM


C. R. Bard  

Murray Hill, New Jersey headquartered C. R. Bard Inc.'s stock edged 0.34% higher, to close the day at $243.24. The stock recorded a trading volume of 559,059 shares. C. R. Bard's shares have gained 5.09% in the last one month, 12.73% in the previous three months, and 28.96% in the past one year. The Company's shares are trading 5.85% and 8.88% above its 50-day and 200-day moving averages, respectively. Shares of the Company, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, are trading at a PE ratio of 34.60. Additionally, the stock has an RSI of 73.13. BCR free research report PDF is just a click away at:

http://stock-callers.com/registration/?symbol=BCR

Glaukos  

On Tuesday, shares in Laguna Hills, California headquartered Glaukos Corp. ended the session 0.04% lower at $45.60 with a total volume of 259,449 shares traded. Glaukos' shares have surged 18.63% in the last one month and 35.51% in the previous three months. Furthermore, the stock has rallied 172.56% in the past one year. Shares of the Company, which develops and commercializes products and procedures designed for the treatment of glaucoma, are trading at a PE ratio of 912.00. The stock is trading 18.90% above its 50-day moving average and 37.09% above its 200-day moving average. Moreover, the Company's shares have an RSI of 74.15. Sign up for your complimentary report on GKOS at:

http://stock-callers.com/registration/?symbol=GKOS


OraSure Technologies  

On Tuesday, shares in Bethlehem, Pennsylvania-based OraSure Technologies Inc. recorded a trading volume of 769,695 shares, which was higher than their three months average volume of 565,670 shares. The stock ended the day 2.05% lower at $11.00. Shares of the Company, which together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the US, Europe, and internationally, are trading at a PE ratio of 31.25. OraSure Technologies' stock has surged 28.96% in the last one month and 29.56% in the previous three months. Furthermore, the stock has rallied 76.00% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 20.72% and 39.10%, respectively. Furthermore, OraSure Technologies' shares have an RSI of 76.06.

On February 09th, 2017, research firm Raymond James upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. Register for free on Stock-Callers.com and download the latest research report on OSUR at:

http://stock-callers.com/registration/?symbol=OSUR

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number:  +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


'/>"/>
SOURCE Chelmsford Park SA
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Hologic erhält FDA-Zulassung für eine neue niedrigdosierte 3D-Mammographie-Lösung (Brust-Tomosynthese) für Brustkrebs-Screening
2. Structure-Based Drug Design Conference in Boston, Starting June 19 PLUS These 62 Start-ups and Small Companies Will Transform Drug Delivery Technology
3. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
4. Hcg-injections.co is a website that provides HCG injections and vitamin B12 injections. These products taken under prescription help customers lose weight. The website is secure and process orders within the same working day and delivers promptly
5. Rehabilitation Robots, Active Prostheses, and Exoskeletons: Market Shares, Strategies, and Forecasts, Worldwide, 2014 to 2020 Research Report Available Online By ResearchMoz.us
6. Bahnbrechende hochleistungsfähige Peptidsynthese-Technologie von CEM wird mit R&D 100 Award ausgezeichnet
7. Foot and Ankle Devices Market by Product, Prostheses, Bracing & by Cause of Injury - Trends & Global Forecasts to 2020
8. Grand Cayman Will Use Oxitec Solution to Suppress Wild Aedes aegypti, the Dangerous Mosquito that Spreads Dengue, Zika and Chikungunya, in an Effort to Help Eliminate These Diseases
9. Are These Biotech Stocks Prescribed for Investors Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
10. How Rewarding Investors Believe These Medical Appliances and Equipment Stocks are? - Edwards Lifesciences, Stryker, Accuray, and ABIOMED
11. How These Biotechs Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NASHVILLE , Tenn. and DALLAS , ... and EndoStim, Inc., announced that the first patients in ... with the EndoStim device in the Lower Esophageal Sphincter ... is a minimally-invasive implantable device designed to provide long-term ... through neurostimulation. GERD affects nearly 65 million ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology:
(Date:4/26/2017)... , ... April 26, 2017 ... ... provides an agile ecosystem and domain expertise for sponsors and CROs to ... and trial supply management (RTSM) software platform. Bioclinica AGILE RTSM ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... a breakthrough topical cream that’s the first in a new class of photodynamic ... the overall appearance of skin, visibly reduce outward signs of aging, and minimize ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... they have signed an agreement to be the preferred physical therapy provider for ... and returning them to Derby City CrossFit as quickly and effectively as possible, ...
(Date:4/25/2017)... ... 2017 , ... A stressful work environment can hurt the physical and emotional ... performance in the workplace. The goal of Clearview Resolution Services has always been to ... Clearview Resolution Services will be shutting down the office early on Fridays. The Clearview ...
(Date:4/25/2017)... CO (PRWEB) , ... April 25, 2017 , ... ... and Liberty attempts to compare student test score performance for the 2015-16 school ... of the state’s voucher programs. Though it highlights important patterns in student test ...
Breaking Medicine News(10 mins):